Lymphokine-activated killer T-cell-originated protein kinase
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lymphokine-activated killer T-cell-originated protein kinase as ChEMBL target CHEMBL4896, mapped to UniProt Q96KB5. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Lymphokine-activated killer T-cell-originated protein kinase matters
Lymphokine-activated killer T-cell-originated protein kinase is reviewed as Lymphokine-activated killer T-cell-originated protein kinase (UniProt Q96KB5); the current evidence base includes 0 approved drugs, 973 compounds, and 90 assays, with lead potency reaching pChEMBL 9.3.
Lymphokine-activated killer T-cell-originated protein kinase Sequence length is 322 aa.
Review this target as Lymphokine-activated killer T-cell-originated protein kinase, mapped to UniProt Q96KB5. Sequence length is 322 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 0 approved drugs, 973 compounds, and 90 assays for this target. The dominant activity type is KI. CHEMBL4445123 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL4445123 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Lymphokine-activated killer T-cell-originated protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q96KB5, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4445123
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL4452726
|
8.8 | IC50 | — |
|
|
No preferred name
CHEMBL3672295
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL4440222
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL4527920
|
8.5 | IC50 | — |